Celltrion develops quadruple-action obesity drug
South Korea's biopharmaceutical company Celltrion said Friday that it has begun primate toxicology studies for CT-G32, its next-generation obesity drug candidate, as the final preclinical stage before human trials.
Original Source
Read the full article at Upi →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.